Stemline prices IPO to raise funds for AML study as cash runs low
This article was originally published in Scrip
With just a few million dollars in the bank, US cancer drug developer Stemline Therapeutics set a range of $11 to $13 per share on 19 July for its initial public offering of 3.5 million shares, but did not announce a date for the IPO, which would generate gross proceeds of $45.5 million at the high end of the stock price target.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.